{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:43:11Z","timestamp":1792532591835,"version":"4.5.0"},"reference-count":126,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Advanced glycation end products (AGEs) are a class of compounds formed by nonenzymatic interactions between reducing sugars and proteins, lipids, or nucleic acids. AGEs can alter the protein structure and activate one of their receptors, specifically the receptor for advanced glycation end products (RAGE). These phenomena impair the functions of cells, extracellular matrix, and tissues. RAGE is expressed by a variety of cells and has been linked to chronic inflammatory autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and Sj\u00f6gren\u2019s syndrome. The soluble (s)RAGE cleavage product is a positively charged 48-kDa cleavage product that retains the ligand binding site but loses the transmembrane and signaling domains. By acting as a decoy, this soluble receptor inhibits the pro-inflammatory processes mediated by RAGE and its ligands. In the present review, we will give an overview of the role of AGEs, sRAGE, and RAGE polymorphisms in several rheumatic diseases. AGE overproduction may play a role in the pathogenesis and is linked to accelerated atherosclerosis. Low serum sRAGE concentrations are linked to an increased cardiovascular risk profile and a poor prognosis. Some RAGE polymorphisms may be associated with increased disease susceptibility. Finally, sRAGE levels can be used to track disease progression.<\/jats:p>","DOI":"10.3390\/ijms24032894","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T04:55:12Z","timestamp":1675313712000},"page":"2894","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases"],"prefix":"10.3390","volume":"24","author":[{"given":"Charlotte","family":"Delrue","sequence":"first","affiliation":[{"name":"Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-3546","authenticated-orcid":false,"given":"Reinhart","family":"Speeckaert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5702-6792","authenticated-orcid":false,"given":"Joris R.","family":"Delanghe","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-4390","authenticated-orcid":false,"given":"Marijn M.","family":"Speeckaert","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Research Foundation-Flanders (FWO), 1000 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.kint.2017.11.034","article-title":"Advanced Glycation End Products in the Pathogenesis of Chronic Kidney Disease","volume":"93","author":"Rabbani","year":"2018","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1681\/ASN.2014101047","article-title":"Uremic Toxicity of Advanced Glycation End Products in CKD","volume":"27","author":"Stinghen","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/rheumatology\/kep199","article-title":"Soluble Receptor for Advanced Glycation End Products: A New Biomarker in Diagnosis and Prognosis of Chronic Inflammatory Diseases","volume":"48","author":"Boulanger","year":"2009","journal-title":"Rheumatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/10715762.2013.815348","article-title":"Advanced Glycoxidation and Lipoxidation End Products (AGEs and ALEs): An Overview of Their Mechanisms of Formation","volume":"47","author":"Vistoli","year":"2013","journal-title":"Free Radic. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cmet.2018.08.014","article-title":"The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality","volume":"28","author":"Chaudhuri","year":"2018","journal-title":"Cell Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","article-title":"Understanding RAGE, the Receptor for Advanced Glycation End Products","volume":"83","author":"Bierhaus","year":"2005","journal-title":"J. Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0167-4889(00)00087-2","article-title":"The Biology of the Receptor for Advanced Glycation End Products and Its Ligands","volume":"1498","author":"Schmidt","year":"2000","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Cell Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI200114002","article-title":"The Multiligand Receptor RAGE as a Progression Factor Amplifying Immune and Inflammatory Responses","volume":"108","author":"Schmidt","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14998","DOI":"10.1016\/S0021-9258(18)42138-2","article-title":"Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins","volume":"267","author":"Neeper","year":"1992","journal-title":"J. Biol. Chem"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","article-title":"Targeting RAGE Signaling in Inflammatory Disease","volume":"69","author":"Hudson","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/10409238.2020.1819194","article-title":"RAGE and Its Ligands: From Pathogenesis to Therapeutics","volume":"55","author":"Jangde","year":"2020","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kim, H.J., Jeong, M.S., and Jang, S.B. (2021). Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136904"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"917108","DOI":"10.1155\/2010\/917108","article-title":"The Receptor for Advanced Glycation End Products (RAGE) and the Lung","volume":"2010","author":"Buckley","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0961203312444495","article-title":"Receptor for Advanced Glycation End Products (RAGE) Polymorphisms Are Associated with Systemic Lupus Erythematosus and Disease Severity in Lupus Nephritis","volume":"21","author":"Martens","year":"2012","journal-title":"Lupus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1515\/bmc-2016-0021","article-title":"Advanced Glycation End Products Mediated Cellular and Molecular Events in the Pathology of Diabetic Nephropathy","volume":"7","author":"Chitra","year":"2016","journal-title":"Biomol. Concepts"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"594622","DOI":"10.3389\/fmed.2020.594622","article-title":"Low Soluble Receptor for Advanced Glycation End Products Precedes and Predicts Cardiometabolic Events in Women With Rheumatoid Arthritis","volume":"7","author":"Nadali","year":"2020","journal-title":"Front. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37525","DOI":"10.1074\/jbc.M111.223438","article-title":"Solution Structure of the Soluble Receptor for Advanced Glycation End Products (SRAGE)","volume":"286","author":"Ikonen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"35507","DOI":"10.1074\/jbc.M806948200","article-title":"Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases","volume":"283","author":"Zhang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2174\/092986706777585013","article-title":"Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target","volume":"13","author":"Geroldi","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1042\/bj20021371","article-title":"Novel Splice Variants of the Receptor for Advanced Glycation End-Products Expressed in Human Vascular Endothelial Cells and Pericytes, and Their Putative Roles in Diabetes-Induced Vascular Injury","volume":"370","author":"Yonekura","year":"2003","journal-title":"Biochem. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar2645","article-title":"Serum Levels of Soluble Receptor for Advanced Glycation End Products and of S100 Proteins Are Associated with Inflammatory, Autoantibody, and Classical Risk Markers of Joint and Vascular Damage in Rheumatoid Arthritis","volume":"11","author":"Chen","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/rheumatology\/ken302","article-title":"Skin Autofluorescence Is Increased in Systemic Lupus Erythematosus but Is Not Reflected by Elevated Plasma Levels of Advanced Glycation Endproducts","volume":"47","author":"Nienhuis","year":"2008","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10408363.2020.1791045","article-title":"The Role of Soluble Receptor for Advanced Glycation End-Products (SRAGE) in the General Population and Patients with Diabetes Mellitus with a Focus on Renal Function and Overall Outcome","volume":"58","author":"Steenbeke","year":"2021","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.gene.6363861","article-title":"RAGE and Arthritis: The G82S Polymorphism Amplifies the Inflammatory Response","volume":"3","author":"Hofmann","year":"2002","journal-title":"Genes Immun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2337\/diabetes.52.3.891","article-title":"Finn-Diane Study Group The Functional-374 T\/A RAGE Gene Polymorphism Is Associated with Proteinuria and Cardiovascular Disease in Type 1 Diabetic Patients","volume":"52","author":"Forsblom","year":"2003","journal-title":"Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/01.ATV.0000160342.20342.00","article-title":"Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men","volume":"25","author":"Falcone","year":"2005","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.2337\/diabetes.50.6.1505","article-title":"Effects of Novel Polymorphisms in the RAGE Gene on Transcriptional Regulation and Their Association with Diabetic Retinopathy","volume":"50","author":"Hudson","year":"2001","journal-title":"Diabetes"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.metabol.2006.09.013","article-title":"Association of the Gly82Ser Polymorphism in the Receptor for Advanced Glycation End Products (RAGE) Gene with Circulating Levels of Soluble RAGE and Inflammatory Markers in Nondiabetic and Nonobese Koreans","volume":"56","author":"Jang","year":"2007","journal-title":"Metabolism"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/ndt\/gfm050","article-title":"Receptor for Advanced Glycation End Products--Soluble Form and Gene Polymorphisms in Chronic Haemodialysis Patients","volume":"22","author":"Mestek","year":"2007","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/07357900701560521","article-title":"Receptor for Advanced Glycation End Products (RAGE)--Soluble Form (SRAGE) and Gene Polymorphisms in Patients with Breast Cancer","volume":"25","author":"Mestek","year":"2007","journal-title":"Cancer Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.mcna.2020.10.006","article-title":"Rheumatoid Arthritis: Early Diagnosis and Treatment","volume":"105","author":"Cush","year":"2021","journal-title":"Med. Clin. N. Am."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5606\/ArchRheumatol.2019.7285","article-title":"Nitroxidized-Albumin Advanced Glycation End Product and Rheumatoid Arthritis","volume":"34","author":"Tarannum","year":"2019","journal-title":"Arch. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1007\/s10067-021-05771-y","article-title":"Advanced Glycation End Products, Advanced Oxidation Protein Products, and Ferric Reducing Ability of Plasma in Patients with Rheumatoid Arthritis: A Focus on Activity Scores","volume":"40","author":"Najafizadeh","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-3083.2007.02001.x","article-title":"Advanced Glycation End Products Upregulate C-Reactive Protein Synthesis by Human Hepatocytes through Stimulation of Monocyte IL-6 and IL-1 Beta Production","volume":"66","author":"Li","year":"2007","journal-title":"Scand. J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Vyt\u00e1sek, R., Sedov\u00e1, L., and Vil\u00edm, V. (2010). Increased Concentration of Two Different Advanced Glycation End-Products Detected by Enzyme Immunoassays with New Monoclonal Antibodies in Sera of Patients with Rheumatoid Arthritis. BMC Musculoskelet. Disord., 11.","DOI":"10.1186\/1471-2474-11-83"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.272.28.17810","article-title":"Activation of the Receptor for Advanced Glycation End Products Triggers a P21(Ras)-Dependent Mitogen-Activated Protein Kinase Pathway Regulated by Oxidant Stress","volume":"272","author":"Lander","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"R817","DOI":"10.1186\/ar1749","article-title":"Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control","volume":"7","author":"Pullerits","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/clinchem\/44.2.250","article-title":"Increased Concentrations of Serum Pentosidine in Rheumatoid Arthritis","volume":"44","author":"Requena","year":"1998","journal-title":"Clin. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00296-004-0518-1","article-title":"The Advanced Glycation End Product Pentosidine Correlates to IL-6 and Other Relevant Inflammatory Markers in Rheumatoid Arthritis","volume":"26","author":"Hein","year":"2005","journal-title":"Rheumatol. Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0004563217733500","article-title":"Increased Serum Concentrations of N\u03b5-Carboxymethyllysine Are Related to the Presence and the Severity of Rheumatoid Arthritis","volume":"55","author":"Knani","year":"2018","journal-title":"Ann. Clin. Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.61.6.488","article-title":"Identification of the Advanced Glycation End Products N(Epsilon)-Carboxymethyllysine in the Synovial Tissue of Patients with Rheumatoid Arthritis","volume":"61","author":"Drinda","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8735926","DOI":"10.1155\/2018\/8735926","article-title":"Methylglyoxal: A Relevant Marker of Disease Activity in Patients with Rheumatoid Arthritis","volume":"2018","author":"Knani","year":"2018","journal-title":"Dis. Markers"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lfs.2016.02.060","article-title":"Methylglyoxal Activates NF-\u039aB Nuclear Translocation and Induces COX-2 Expression via a P38-Dependent Pathway in Synovial Cells","volume":"149","author":"Lin","year":"2016","journal-title":"Life Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"C1510","DOI":"10.1152\/ajpcell.00252.2008","article-title":"Methylglyoxal Mediates Vascular Inflammation via JNK and P38 in Human Endothelial Cells","volume":"295","author":"Yamawaki","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.2147\/JIR.S327736","article-title":"Transthyretin and Receptor for Advanced Glycation End Product\u2019s Differential Levels Associated with the Pathogenesis of Rheumatoid Arthritis","volume":"14","author":"Monu","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00296-007-0408-4","article-title":"Measurement of Advanced Glycation Endproducts in Skin of Patients with Rheumatoid Arthritis, Osteoarthritis, and Dialysis-Related Spondyloarthropathy Using Non-Invasive Methods","volume":"28","author":"Matsumoto","year":"2007","journal-title":"Rheumatol. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2008.094151","article-title":"Rheumatoid Arthritis versus Diabetes as a Risk Factor for Cardiovascular Disease: A Cross-Sectional Study, the CARRE Investigation","volume":"68","author":"Peters","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/art.10089","article-title":"Accelerated Atherosclerosis: An Extraarticular Feature of Rheumatoid Arthritis?","volume":"46","author":"McColl","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","article-title":"High Incidence of Cardiovascular Events in a Rheumatoid Arthritis Cohort Not Explained by Traditional Cardiac Risk Factors","volume":"44","author":"Williams","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1756-185X.2011.01679.x","article-title":"Advanced Glycation End-Products Inhibition Improves Endothelial Dysfunction in Rheumatoid Arthritis","volume":"15","author":"Syngle","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/dc07-1755","article-title":"Skin Autofluorescence: A Tool to Identify Type 2 Diabetic Patients at Risk for Developing Microvascular Complications","volume":"31","author":"Gerrits","year":"2008","journal-title":"Diabetes Care"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1210\/jc.2007-1817","article-title":"The Role of Advanced Glycation End Products in Progression and Complications of Diabetes","volume":"93","author":"Goh","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.33549\/physiolres.931147","article-title":"Advanced Glycation End-Product Pentosidine Is Not a Relevant Marker of Disease Activity in Patients with Rheumatoid Arthritis","volume":"56","author":"Senolt","year":"2007","journal-title":"Physiol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00296-007-0419-1","article-title":"Etanercept Reduces the Oxidative Stress Marker Levels in Patients with Rheumatoid Arthritis","volume":"28","author":"Kageyama","year":"2008","journal-title":"Rheumatol. Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar622","article-title":"Advanced Glycation End-Product (AGE)-Damaged IgG and IgM Autoantibodies to IgG-AGE in Patients with Early Synovitis","volume":"5","author":"Newkirk","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2249.2000.01188.x","article-title":"An Autoantibody Targeting Glycated IgG Is Associated with Elevated Serum Immune Complexes in Rheumatoid Arthritis (RA)","volume":"120","author":"Tai","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.humimm.2012.10.008","article-title":"Preferential Recognition of Epitopes on AGE\u2013IgG by the Autoantibodies in Rheumatoid Arthritis Patients","volume":"74","author":"Ahmad","year":"2013","journal-title":"Hum. Immunol."},{"key":"ref_58","first-page":"319","article-title":"Association between IgM Response to IgG Damaged by Glyoxidation and Disease Activity in Rheumatoid Arthritis","volume":"27","author":"Lucey","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/iub.582","article-title":"Physicochemical Studies on Glycation-Induced Structural Changes in Human IgG","volume":"64","author":"Ahmad","year":"2012","journal-title":"IUBMB Life"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijbiomac.2018.06.040","article-title":"Moinuddin, null Methylglyoxal Modified IgG Generates Autoimmune Response in Rheumatoid Arthritis","volume":"118","author":"Islam","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_61","first-page":"1129","article-title":"Advanced Glycation Endproducts (AGE) on IgG, a Target for Circulating Antibodies in North American Indians with Rheumatoid Arthritis (RA)","volume":"44","author":"Newkirk","year":"1998","journal-title":"Cell Mol. Biol. (Noisy-le-Grand)"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF03325227","article-title":"Advanced Glycation End Products and Their Circulating Receptors Predict Cardiovascular Disease Mortality in Older Community-Dwelling Women","volume":"21","author":"Semba","year":"2009","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_63","first-page":"654","article-title":"Immunohistochemical and Ultrastructural Detection of Advanced Glycation End Products in Atherosclerotic Lesions of Human Aorta with a Novel Specific Monoclonal Antibody","volume":"147","author":"Kume","year":"1995","journal-title":"Am. J. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1172\/JCI119180","article-title":"Increased Accumulation of the Glycoxidation Product N(Epsilon)-(Carboxymethyl)Lysine in Human Tissues in Diabetes and Aging","volume":"99","author":"Schleicher","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/hc0702.104183","article-title":"Advanced Glycation End Products Activate Endothelium through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses","volume":"105","author":"Basta","year":"2002","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1186\/ar3538","article-title":"Advanced Glycation Endproducts Are Increased in Rheumatoid Arthritis Patients with Controlled Disease","volume":"13","author":"Hinkema","year":"2011","journal-title":"Arthritis. Res. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/art.21524","article-title":"Increased Expression of Receptor for Advanced Glycation End Products by Synovial Tissue Macrophages in Rheumatoid Arthritis","volume":"54","author":"Sunahori","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10456-008-9093-5","article-title":"Convergence and Amplification of Toll-like Receptor (TLR) and Receptor for Advanced Glycation End Products (RAGE) Signaling Pathways via High Mobility Group B1 (HMGB1)","volume":"11","author":"Buurman","year":"2008","journal-title":"Angiogenesis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/35012626","article-title":"Blockade of RAGE-Amphoterin Signalling Suppresses Tumour Growth and Metastases","volume":"405","author":"Taguchi","year":"2000","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2796.2003.01303.x","article-title":"HMGB1 Is a Potent Trigger of Arthritis","volume":"255","author":"Andersson","year":"2004","journal-title":"J. Intern. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2005.01534.x","article-title":"RAGE Is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Macrophages","volume":"61","author":"Kokkola","year":"2005","journal-title":"Scand J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/ard.2008.103739","article-title":"Calprotectin (a Major S100 Leucocyte Protein) Predicts 10-Year Radiographic Progression in Patients with Rheumatoid Arthritis","volume":"69","author":"Hammer","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3899\/jrheum.110091","article-title":"Serum Levels of HMGB1 in Postmenopausal Patients with Rheumatoid Arthritis: Associations with Proinflammatory Cytokines, Acute-Phase Reactants, and Clinical Disease Characteristics","volume":"38","author":"Pullerits","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/kem141","article-title":"Synovial Fluid Expression of Autoantibodies Specific for RAGE Relates to Less Erosive Course of Rheumatoid Arthritis","volume":"46","author":"Pullerits","year":"2007","journal-title":"Rheumatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semarthrit.2012.07.002","article-title":"Serum Soluble Receptor for Advanced Glycation End Products Levels and Aortic Augmentation Index in Early Rheumatoid Arthritis\u2014A Prospective Study","volume":"42","author":"Tam","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/14397595.2018.1551107","article-title":"Relationship between Serum-Soluble Receptor for Advanced Glycation End Products (SRAGE) and Disease Activity in Rheumatoid Arthritis Patients","volume":"29","author":"Jafarpour","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_77","first-page":"3450","article-title":"An Investigation of the Relationship between Rheumatological Diseases and Soluble Receptor for Advanced Glycation End Products","volume":"26","author":"Okuyucu","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Heslinga, M., Teunissen, C., Agca, R., van der Woude, D., Huizinga, T., van Laar, J., den Broeder, A., Lems, W., and Nurmohamed, M. (2022). NT-ProBNP and SRAGE Levels in Early Rheumatoid Arthritis. Scand. J. Rheumatol., 1\u20137.","DOI":"10.1080\/03009742.2022.2042975"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3132\/dvdr.2009.002","article-title":"Receptor for Advanced Glycation End-Products (RAGE) and Soluble RAGE (SRAGE): Cardiovascular Implications","volume":"6","author":"Lindsey","year":"2009","journal-title":"Diab. Vasc. Dis. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehm089","article-title":"Low-Grade Inflammation and Hypoadiponectinaemia Have an Additive Detrimental Effect on Aortic Stiffness in Essential Hypertensive Patients","volume":"28","author":"Tsioufis","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2741\/3315","article-title":"RAGE Signaling in Inflammation and Arterial Aging","volume":"14","author":"Lin","year":"2009","journal-title":"Front. Biosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/ar3398","article-title":"The Expression of the Receptor for Advanced Glycation End-Products (RAGE) in RA-FLS Is Induced by IL-17 via Act-1","volume":"13","author":"Heo","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"35933","DOI":"10.1038\/srep35933","article-title":"Overexpression of Soluble RAGE in Mesenchymal Stem Cells Enhances Their Immunoregulatory Potential for Cellular Therapy in Autoimmune Arthritis","volume":"6","author":"Park","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/cdd.2013.158","article-title":"Immunobiology of Mesenchymal Stem Cells","volume":"21","author":"Ma","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management Strategies and Future Directions for Systemic Lupus Erythematosus in Adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cden.2013.06.003","article-title":"Systemic Lupus Erythematosus: Epidemiology, Pathophysiology, Manifestations, and Management","volume":"57","author":"Fortuna","year":"2013","journal-title":"Dent. Clin. N. Am."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5694\/j.1326-5377.1997.tb140110.x","article-title":"10. Systemic Lupus Erythematosus","volume":"166","author":"Rasaratnam","year":"1997","journal-title":"Med. J. Aust."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s12016-017-8640-5","article-title":"Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus","volume":"55","author":"Bakshi","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Nowak, A., Przywara-Chowaniec, B., Damasiewicz-Bodzek, A., Blachut, D., Nowalany-Kozielska, E., and Tyrpie\u0144-Golder, K. (2021). Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (SRAGE) in Women Suffering from Systemic Lupus Erythematosus (SLE). Cells, 10.","DOI":"10.3390\/cells10123523"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Ene, C.D., Georgescu, S.R., Tampa, M., Matei, C., Mitran, C.I., Mitran, M.I., Penescu, M.N., and Nicolae, I. (2021). Cellular Response against Oxidative Stress, a Novel Insight into Lupus Nephritis Pathogenesis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080693"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Chen, D.-Y., Chen, Y.-M., Lin, C.-C., Hsieh, C.-W., Wu, Y.-C., Hung, W.-T., Chen, H.-H., and Lan, J.-L. (2015). The Potential Role of Advanced Glycation End Products (AGEs) and Soluble Receptors for AGEs (SRAGE) in the Pathogenesis of Adult-Onset Still\u2019s Disease. BMC Musculoskelet Disord., 16.","DOI":"10.1186\/s12891-015-0569-3"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"R181","DOI":"10.1186\/ar3145","article-title":"Small Artery Elasticity Is Decreased in Patients with Systemic Lupus Erythematosus without Increased Intima Media Thickness","volume":"12","author":"Nienhuis","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/rheumatology\/kem215","article-title":"Accumulation of Advanced Glycation Endproducts in Patients with Systemic Lupus Erythematosus","volume":"46","author":"Graaff","year":"2007","journal-title":"Rheumatology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203306069972","article-title":"Traditional and Non-Traditional Risk Factors Contribute to the Development of Accelerated Atherosclerosis in Patients with Systemic Lupus Erythematosus","volume":"15","author":"Freire","year":"2006","journal-title":"Lupus"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10719-016-9694-y","article-title":"Pathways of the Maillard Reaction under Physiological Conditions","volume":"33","author":"Henning","year":"2016","journal-title":"Glycoconj. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-3083.2012.02691.x","article-title":"The Plasma Level of Soluble Receptor for Advanced Glycation End Products Is Decreased in Patients with Systemic Lupus Erythematosus","volume":"75","author":"Ma","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1546-0096-12-50","article-title":"The Presence of High Mobility Group Box-1 and Soluble Receptor for Advanced Glycation End-Products in Juvenile Idiopathic Arthritis and Juvenile Systemic Lupus Erythematosus","volume":"12","author":"Bobek","year":"2014","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Tang, K.-T., Hsieh, T.-Y., Chao, Y.-H., Lin, M.-X., Chen, Y.-H., Chen, D.-Y., and Lin, C.-C. (2017). Plasma Levels of High-Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End Products in Primary Antiphospholipid Antibody Syndrome Patients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178404"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203314559631","article-title":"Members of the Receptor for Advanced Glycation End Products Axis as Potential Therapeutic Targets in Patients with Lupus Nephritis","volume":"24","author":"Yu","year":"2015","journal-title":"Lupus"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fimmu.2019.00460","article-title":"Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome","volume":"10","author":"Manganelli","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.micinf.2004.08.004","article-title":"RAGE (Receptor for Advanced Glycation End Products): A Central Player in the Inflammatory Response","volume":"6","author":"Chavakis","year":"2004","journal-title":"Microbes. Infect."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/1871530320666200506082848","article-title":"Association Between SRAGE and Arterial Stiffness in Women with Systemic Lupus Erythematosus","volume":"21","author":"Wang","year":"2021","journal-title":"Endocr. Metab. Immune. Disord. Drug Targets"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Lan, L., Han, F., Lang, X., and Chen, J. (2016). Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159964"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mnfr.200500007","article-title":"Genetic Variability in the RAGE Gene: Possible Implications for Nutrigenetics, Nutrigenomics, and Understanding the Susceptibility to Diabetic Complications","volume":"49","year":"2005","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_105","first-page":"2067353","article-title":"Pathological Implications of Receptor for Advanced Glycation End-Product (AGER) Gene Polymorphism","volume":"2019","author":"Jabaudon","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1053\/meta.2001.26757","article-title":"Polymorphisms 1704G\/T and 2184A\/G in the RAGE Gene Are Associated with Antioxidant Status","volume":"50","author":"Znojil","year":"2001","journal-title":"Metabolism"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/art.20093","article-title":"Sj\u00f6gren\u2019s Syndrome Associated with Systemic Lupus Erythematosus: Clinical and Laboratory Profiles and Comparison with Primary Sj\u00f6gren\u2019s Syndrome","volume":"50","author":"Manoussakis","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00296-008-0529-4","article-title":"Decreased Levels of Soluble Receptor for Advanced Glycation End Products in Patients with Primary Sj\u00f6gren\u2019s Syndrome","volume":"28","author":"Stewart","year":"2008","journal-title":"Rheumatol. Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/03009740310004775","article-title":"Receptor of Advanced Glycation End Product (RAGE) Expression in the Minor Salivary Glands of Patients with Sj\u00f6gren\u2019s Syndrome: A Preliminary Study","volume":"33","author":"Katz","year":"2004","journal-title":"Scand. J. Rheumatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/acr.23420","article-title":"Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations with Extraglandular Involvement and Disease Activity in Sj\u00f6gren\u2019s Syndrome","volume":"70","author":"Kanne","year":"2018","journal-title":"Arthritis Care Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1084\/jem.20030800","article-title":"The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins: A Novel Pathway for Inflammatory Cell Recruitment","volume":"198","author":"Chavakis","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-Onset Still\u2019s Disease","volume":"13","author":"Jamilloux","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_113","first-page":"2189","article-title":"Proinflammatory Cytokine Profiles in Sera and Pathological Tissues of Patients with Active Untreated Adult Onset Still\u2019s Disease","volume":"31","author":"Chen","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.nut.2011.11.005","article-title":"Circulating Selenium and Carboxymethyl-Lysine, an Advanced Glycation Endproduct, Are Independent Predictors of Anemia in Older Community-Dwelling Adults","volume":"28","author":"Roy","year":"2012","journal-title":"Nutrition"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.3899\/jrheum.140651","article-title":"Serum S100A12 May Be a Useful Biomarker of Disease Activity in Adult-Onset Still\u2019s Disease","volume":"41","author":"Bae","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"G823","DOI":"10.1152\/ajpgi.00115.2010","article-title":"The Functional -374T\/A Polymorphism of the Receptor for Advanced Glycation End Products May Modulate Crohn\u2019s Disease","volume":"300","author":"Friedrichs","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nm831","article-title":"Suppression of Experimental Autoimmune Encephalomyelitis by Selective Blockade of Encephalitogenic T-Cell Infiltration of the Central Nervous System","volume":"9","author":"Yan","year":"2003","journal-title":"Nat. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/mol.52.1.54","article-title":"Recombinant Advanced Glycation End Product Receptor Pharmacokinetics in Normal and Diabetic Rats","volume":"52","author":"Renard","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile Idiopathic Arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile Idiopathic Arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/rheumatology\/kep383","article-title":"Possible Environmental Determinants of Juvenile Idiopathic Arthritis","volume":"49","author":"Ellis","year":"2010","journal-title":"Rheumatology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3899\/jrheum.110058","article-title":"Soluble Receptor for Advanced Glycation Endproducts Is Decreased in Patients with Juvenile Idiopathic Arthritis (ERA Category) and Inversely Correlates with Disease Activity and S100A12 Levels","volume":"38","author":"Myles","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e3399","DOI":"10.1002\/jgm.3399","article-title":"AGER Gene Variant as a Risk Factor for Juvenile Idiopathic Arthritis","volume":"24","author":"Bakutenko","year":"2022","journal-title":"J. Gene. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3818196","DOI":"10.1155\/2020\/3818196","article-title":"Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects","volume":"2020","author":"Perrone","year":"2020","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/157016110790226642","article-title":"Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation","volume":"8","author":"Lanati","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.freeradbiomed.2007.06.017","article-title":"Decreased Plasma Soluble RAGE in Patients with Hypercholesterolemia: Effects of Statins","volume":"43","author":"Santilli","year":"2007","journal-title":"Free Radic. Biol. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2894\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:22:09Z","timestamp":1760120529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":126,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24032894"],"URL":"https:\/\/doi.org\/10.3390\/ijms24032894","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}